Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of semaglutide once weekly versus insulin glargine once daily as add on to metformin with or without sulphonylurea in insulin-naive subjects with type 2 diabetes

Next Previous
Trial Profile

Efficacy and safety of semaglutide once weekly versus insulin glargine once daily as add on to metformin with or without sulphonylurea in insulin-naive subjects with type 2 diabetes

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 25 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Semaglutide (Primary) ; Insulin glargine; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms SUSTAIN 4
  • Sponsors Novo Nordisk

    • Most Recent Events

    • 11 Jun 2019 Post hoc analysis results from SUSTAIN 1-5 and 7 studies were presented at the 79th Annual Scientific Sessions of the American Diabetes Association.
    • 11 Jun 2019 Results of post hoc analysis assessing the proportion of semaglutide-treated subjects achieving clinically relevant responses by baseline HbA1c and body weight across SUSTAIN 1-5 and 7 trials presented at the 79th Annual Scientific Sessions of the American Diabetes Association
    • 11 Jun 2019 Results of post-hoc analysis SUSTAIN 2-5 and 7 assessing if weight loss was associated with patient-reported health-related quality of life presented at the 79th Annual Scientific Sessions of the American Diabetes Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top